Less Ads, More Data, More Tools Register for FREE

AstraZeneca Says Durvalumab Phase III Trial Supports Clinical Activity

Fri, 18th Dec 2015 07:19

LONDON (Alliance News) - AstraZeneca PLC said Friday preliminary findings from its phase III trial of durvalumab in third line or later-stage therapy for patients with non-small cell lung cancer supports the durvalumab's clinical activity.

However, the company said it now believes it is unlikely the trial can be used for the regulatory submission of the drug as a monotherapy, although it will make that decision following a full analysis of the data.

The trial investigated the efficacy and tolerability of the drug for patients who had received at least two prior systemic treatment regimens, including platinum-based chemotherapy, and who have limited options for further therapy.

AstraZeneca said a full evaluation of the trial data is ongoing, with results to be presented at a scientific congress in 2016.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2015 Alliance News Limited. All Rights Reserved.

Related Shares

More News

Pressure grows to recall MPs to debate UK vaccine passports proposal

Pressure grows to recall MPs to debate UK vaccine passports proposal

2 Aug 21 13:00

AstraZeneca's Saphnelo gets FDA approval in US for systemic lupus

AstraZeneca's Saphnelo gets FDA approval in US for systemic lupus

2 Aug 21 08:37

AstraZeneca's Saphnelo receives FDA approval

(Sharecast News) - Drugmaker AstraZeneca said on Monday that Saphnelo had been approved in the US for the treatment of adult patients already receiving standard therapy for moderate to severe systemic lupus erythematosus.

2 Aug 21 08:07

AstraZeneca boss not yet sure if booster shots will be needed

(Sharecast News) - AstraZeneca does not know yet whether so-called 'booster' shots of its Covid-19 vaccine will be needed or not.

29 Jul 21 14:48

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.